Company / Named in our posts
Alumis Inc..
Follow Alumis Inc.Alumis is a late-stage biopharma company developing next-generation targeted therapies for immune-mediated diseases.[1]
01Deal
Deals on Carrywatch
Every deal that names Alumis Inc., and its role in each.
Alumis Inc. / ACELYRIN, Inc.
Alumis Inc. agrees to buy ACELYRIN, Inc.
See deal detailsDeal Web
Alumis Inc. and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
2 fiscal years of figures as Alumis Inc. reported them.
News
Loading headlines.
Sources
As of 25 Oct 2026.
- 01Exhibit 99.1 — Alumis Completes Merger with ACELYRIN
U.S. Securities and Exchange Commission · Researched 25 Oct 2026
- 02Form 8-K — Alumis Inc.
U.S. Securities and Exchange Commission · Researched 25 Oct 2026
Deal posts naming Alumis Inc.:
- P01